Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases

Expert Review of Clinical Immunology

Volumn 7, Issue 2, 2011, Pages 193-203

  Small, Trudy N ^a   Cowan, Morton J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

hematopoietic cell transplantation; HLA matched sibling; immune reconstitution; immunization; T cell depletion; unrelated donor

Indexed keywords

ACICLOVIR; CD45RA ANTIGEN; CYCLOPHOSPHAMIDE; DIPHTHERIA TETANUS VACCINE; FLUDARABINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE PLUS HEPATITIS B VACCINE; HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS TOXIN; PNEUMOCOCCUS VACCINE; RITUXIMAB; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CHICKENPOX; DIPHTHERIA; DRUG MEGADOSE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAEMOPHILUS INFECTION; HEMAGGLUTINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HERPES ZOSTER; HLA MATCHING; HUMAN; IMMUNIZATION; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MEASLES; MUMPS; NONHUMAN; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; REVIEW; RUBELLA; SEROCONVERSION; SINGLE DRUG DOSE; T CELL DEPLETION; TETANUS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BACTERIAL VACCINES; CHILD; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DISEASE SUSCEPTIBILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOCOMPROMISED HOST; PRACTICE GUIDELINES AS TOPIC; VIRAL VACCINES;

EID: 79953104954     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.103     Document Type: Review

References (103)

1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N. Engl. J. Med. 357(15), 1472-1475 (2007). (Pubitemid 47572632)
2. Prevention of Pneumococcal Disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 46(RR-8), 1-24 (1997).
3. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb. Mortal. Wkly Rep. 59(35), 1057-1062 (2010).
4. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin. Proc. 84(3), 274-280 (2009).
5. Oxman MN, Levin MJ, Johnson GR et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352(2), 2271-2284 (2005).
6. Broder KR, Cortese MM, Iskander JK et al. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 55(RR-17), 1-34 (2006).
7. De Serres G, Shadmani R, Duval B et al. Morbidity of pertussis in adolescents and adults. J. Infect. Dis. 182(1), 174-179 (2000). (Pubitemid 30497802)
8. Ada G. Vaccines and vaccinations. N. Engl. J. Med. 345(14), 1042-1053 (2001).
9. Engelhard D, Cordonnier C, Shaw PJ et al. Early and late invasive pneumococcal infection following stem cell transplantation: A European bone marrow transplantation survey. Br. J. Haematol. 117(2), 444-450 (2002). (Pubitemid 34451164)
10. Socie G, Salooja N, Cohen A et al. Non-malignant late effects after allogeneic stem cell transplantation. Blood 101(9), 3373-3385 (2003). (Pubitemid 36857917)
11. Chen CS, Boeckh M, Seidel K et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant. 32(5), 515-522 (2003). (Pubitemid 37160968)
12. Kumar D, Humar A, Plevneshi A et al. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: A decade of prospective population-based surveillance. Bone Marrow Transplant. 41(8), 743-747 (2008). (Pubitemid 351587040)
13. Koc Y, Miller KB, Schenkein DP et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome. Biol. Blood Marrow. Transplant. 6(1), 44-49 (2000).
14. Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr. 128(3), 353-356 (1996). (Pubitemid 26087535)
15. Leung TF, Chik KW, Li CK et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant. 25(2), 167-167 (2000).
16. Onozawa M, Hashino S, Haseyama Y et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol. Blood Marrow Transpl. 15(6), 724-729 (2009).
17. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant. 42(10), 637-641 (2008).
18. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: Risk factors, mortality, and the effect of antiviral therapy. Clin. Infect. Dis. 39(9), 1300-1306 (2004). (Pubitemid 39458515)
19. Martino R, Porras RP, Rabella N et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol. Blood Marrow Transplant. 11(10), 781-796 (2005). (Pubitemid 41403760)
20. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 36(10), 897-900 (2005). (Pubitemid 41655617)
21. Papadopoulos EB, Young JW, Kernan NA et al. Use of the tetanus toxoid, reduced dose diphtheria and pertussis vaccine (TDaP) in allogeneic transplant (alloHCT) recipients. Blood 112, 2214 (2008) (Abstract).
22. Small TN, Zelenetz AD, Noy A et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (TDaP) after autologous peripheral blood stem cell transplantation. Biol. Blood Marrow. Transplant. 15(12), 1538-1542 (2009).
23. Ljungman P, Cordonnier C, Einsele H et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 44(8), 521-526 (2009). Details the most recent international guidelines for revaccination of patients following autologous and allogeneic hematopoietic cell transplant (HCT).
24. Small TN. Vaccination of hematopoietic cell transplant recipients. In:Hematopoietic Cell Transplantation (Fourth Edition) Appelbaum F, Forman S, Blume KG, Thomas ED (Eds). Blackwell Science, Malden, MA, USA, 108, 1664-1670 (2009).
25. Ljungman P, Wiklund-Hammarsten M, Duraj V et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J. Infect. Dis. 162(2), 496-500 (1990). (Pubitemid 20239969)
26. Ljungman P, Aschan J, Barkholt L et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant. 34(7), 589-593 (2004). (Pubitemid 39341538)
27. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103(3), 777-783 (2004). (Pubitemid 38129532)
28. Nordøy T, Husebekk A, Aaberge IS et al. Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant. 28(7), 681-687 (2001). (Pubitemid 33014602)
29. Hammarström V, Pauksen K, Björkstrand B, Simonsson B, Oberg G, Ljungman P. Tetanus immunity in autologous bone marrow and blood stem cell transplant recipients. Bone Marrow Transplant. 22(1), 67-71 (1998). (Pubitemid 28330538)
30. Small TN, Rice RD, McCullagh E et al. Vaccine efficacy following autologous peripheral blood stem cell transplant for lymphoma. Blood 110(11), 603 (2007).
31. Ljungman P, Cordonnier C, de Bock R et al. Immunisations after bone marrow transplantation: Results of a European survey and recommendations from the infectious diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 15(3), 455-460 (1995).
32. Ljungman P, Engelhard D, de la Cámara R et al. Vaccination of stem cell transplant recipients: Recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 35(8), 737-746 (2005). (Pubitemid 40613780)
33. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb. Mortal. Wkly Rep. 49, 1-128 (2000).
34. Villa LL, Ault KA, Giuliano AR. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24(27-28), 5571-5583 (2006). (Pubitemid 44172918)
35. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 54(RR-7), 1-21 (2005).
36. Ljungman P, Small TN. Update to vaccination guidelines. Biol. Blood Marrow Transplant. 16(11), 1608-1609 (2011).
37. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), MMWR Morb. Mortal. Wkly Rep. 59(9), 258-261 (2010).
38. Small TN, Keever CA, Weiner-Fedus S et al. B cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: Arecapitulation of normal B cell ontogeny. Blood 76(8), 1647-1656 (1990). (Pubitemid 20364032)
39. Small TN, Papadopoulos EB, Boulad F et al. Comparison of immune reconstitution following unrelated and related T cell depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions. Blood 93(2), 467-480 (1999). (Pubitemid 29035728)
40. Storek J, Joseph A, Dawson MA, Douek DC, Storer B, Maloney DG. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation 73(7), 1154-1158 (2002). (Pubitemid 34415453)
41. Storek J. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 98(2), 489-491 (2001).
42. Keever-Taylor CA, Wagner JE, Kernan NA et al. Comparison of immune recovery in recipients of unmanipulated vs T-celldepleted grafts from unrelated donors in a multicenter randomized Phase II-III trial (T-cell depletion trial). Bone Marrow Transplant. 45(3) 587-589 (2010).
43. Pao M, Papadopoulos EB, Boulad F et al. Response to immunizations following allogeneic HCT with adjuvant rituximab therapy. Blood 106(11), 3242 (2005).
44. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant. 7(2), 89-93 (1991).
45. Parkkali T, Olander R-M, Ruutu T et al. A randomized comparison between early and late vaccination with tetanus toxoid after allogeneic bone marrow transplantation. Bone Marrow Transplant. 19(9), 933-938 (1997). (Pubitemid 27217662)
46. Parkkali T, Stenvik M, Ruutu T, Hovi T, Volin L, Ruutu P. Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant. 20(8), 663-668 (1997). (Pubitemid 27477580)
47. Parkkali T, Käyhty H, Hovi T et al. A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant. 39(3), 179-188 (2007). (Pubitemid 46178753)
48. Molrine DC, Guinan EC, Antin JH et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 87(7), 3012-3018 (1991). (Pubitemid 26102254)
49. Storek J, Dawson MA, Lim LC et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant. 33(3), 337-346 (2004). (Pubitemid 38256567)
50. Jaffe D, Papadopoulos EB, Young JW et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell transplantation (HCT). Blood 108(7), 2470-2475 (2006). (Pubitemid 44497535)
51. Patel SR, Ortin M, Cohen BJ et al. Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin. Infect. Dis. 44(5), 625-634 (2007).
52. Hammarström V, Pauksen K, Azinge J, Oberg G, Ljungman P. Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: The influence of graft versus host reaction. Support Care Cancer 1(4), 195-199 (1993).
53. Barra A, Cordonnier C, Preziosi MP et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J. Infect. Dis. 166(5), 1021-1028 (1992).
54. Guinan EC, Molrine DC, Antin JH et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 57(5), 677-684 (1994). (Pubitemid 24106765)
55. Avanzini MA, Carra AM, Maccario R et al. Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. J. Clin. Immunol. 15(3), 137-144 (1995).
56. Spoulou V, Victoratos P, Ioannidis JPA, Grafakos S. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. J. Infect. Dis. 182(3), 965-969 (2000).
57. Avanzini M, Locatelli F, Santos C et al. Blymphocyte reconstitution after hematopoietic stem cell transplantation: Functional immaturity and slow recovery of memory CD27 B cells. Exp. Hematol. 33(4), 480-486 (2005). (Pubitemid 40387631)
58. Greinix HT, Pohlreich D, Kouba M et al. Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus-host disease. Biol. Blood Marrow. Transplant. 14(2), 208-219 (2008).
59. D'Orsogna LJ, Wright MP, Krueger RG et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and IgM memory B cells. Biol. Blood Marrow. Transplant. 15(7), 795-803 (2009).
60. Pao M, Papadopoulos EB, Chou J et al. Response to pneumococcal (PNCRM7) and Haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol. Blood Marrow. Transplant. 14(11), 1022-1030 (2008).
61. Molrine DC, Antin JH, Guinan EC et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 101(3), 831-836 (2003). (Pubitemid 36139347)
62. Antin J, Guinan EC, Avigan D et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 11(3), 213-222 (2005). (Pubitemid 40287920)
63. Meisel R, Kuypers L, Dirksen U et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell Transplantation. Blood 109(6), 2322-2326 (2007). (Pubitemid 46425870)
64. Cordonnier C, Labopin M, Chesnel V et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin. Infect. Dis. 48(10), 1392-1401 (2009). A double-blind, randomized, multicenter study on PCV-7 following allogenic HCT.
65. Cordonnier C, Labopin M, Chesnel V et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial. Vaccine 28(15), 2730-2734 (2010).
66. Meerveld-Eggink A, van der Velden AMT, Ossenkoppele GJ et al. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 15(2), 1523-1530 (2009). One of the few studies on vaccine responses in recipients of nonmyeloablative HCTs.
67. Centers for Disease Control and Prevention. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm. Rep. 40 (RR-13), 1-25 (1991).
68. Machado CM. Reimmunization after bone marrow transplantation-current recommendations and perspectives. Braz. J. Med. Biol. Res. 37(1), 151-158 (2004). (Pubitemid 38240157)
69. Machado CM, Rocha IF, Diomede B et al. Effectiveness of hepatitis B vaccination and persistence of immunity after BMT. Presented at: The Ninth International Symposium on Infections in the Immunocompromised Host. Assisi, Italy, 23-26 June 1997.
70. Centers for Disease Control and Prevention. Update: Mumps outbreak - New York and New Jersey, June 2009-January 2010. MMWR Morb. Mortal. Wkly Rep. 59(5), 125-129 (2010).
71. Centers for Disease Control and Prevention. Multistate measles outbreak associated with an international youth sporting event - Pennsylvania, Michigan, and Texas, August-September. MMWR Morb. Mortal. Wkly Rep. 57(7), 169-173 (2007).
72. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine. Pediatrics 101(1), 129-133 (1998).
73. Pauksen K, Linde A, Ljungman P et al. Specific T and B cell immunity to measles after allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant. 16(6), 807-813 (1995). (Pubitemid 26008441)
74. Ljungman P, Fridell E, Lönnqvist B et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J. Infect. Dis. 159(4), 610-615 (1989). (Pubitemid 19105613)
75. King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant. 17(4), 633-636 (1996). (Pubitemid 26125718)
76. Machado CM, Goncalves FB, Pannuti CS, Dulley FL, de Souza VA. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood 99(1), 83-87 (2002).
77. Machado CM, de Souza VA, Sumita LM et al. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant. 35(8), 787-791 (2005). (Pubitemid 40613786)
78. Small TN, Papadopoulos EB, Boulad F et al. Vaccine responses following unmodified or T cell depleted unrelated and mismatched related HCT. Blood 104, (2004) (Abstract 2226).
79. Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 35(11), 1065-1069 (2005). (Pubitemid 40767194)
80. Kim DH, Messner H, Minden M et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: Low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl. Infect. Dis. 10(2), 90-98 (2008). (Pubitemid 351393079)
81. Erard V, Guthrie KA, Varley C et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: No evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110(8), 3071-3077 (2007). (Pubitemid 350006963)
82. Curtis KK, Connolly MK, Northfelt DW. Live, attenuated varicella zoster vaccination of an immunocompromised patient. J. Gen. Intern. Med. 23(5), 648-649 (2008).
83. Sartori AM. A review of the varicella vaccine in immunocompromised hosts. Int. J. Infect. Dis. 8(5), 259-270 (2004). (Pubitemid 39119849)
84. Chaves SS, Gargiullo P, Zhang JX et al. Loss of vaccine-induced immunity to varicella over time. N. Engl. J. Med. 356(11), 1121-1129 (2007). (Pubitemid 46425596)
85. Marin M, Güris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 56(RR-4), 1-40 (2007).
86. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 347(1), 26-34 (2002). (Pubitemid 34728954)
87. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 20(5), 381-383 (1997). (Pubitemid 27390411)
88. Ljungman P, Wang FZ, Nilsson C, Solheim V, Linde A. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: A pilot study. Support Care Cancer 11(11), 739-741 (2003). (Pubitemid 37432632)
89. Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 45(11) 1602-1606 (2010). One of the few studies on varicella response following allogenic HCT.
90. Small TN, Kernan NA, Prockop S. Immunogenicity of the live attenuated varicella vaccine following allogeneic HCT. Blood 114(22), 468 (2009).
91. Engelhard D, Nagler A, Hardan I et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T celldepleted and autologous BMT recipients. Bone Marrow Transplant. 11(1), 1-5 (1993). (Pubitemid 23086839)
92. Pauksen K, Linde A, Hammarström V et al. Granulocyte-macrophage colonystimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients. Clin. Infect. Dis. 30(6), 342-348 (2000). (Pubitemid 30131544)
93. Gandhi MK, Egner W, Sizer L et al. Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and bone marrow transplant recipients. Bone Marrow Transplant. 28(8), 775-781 (2001). (Pubitemid 33085571)
94. Haining WN, Evans JW, Seth NS et al. Measuring T cell immunity to influenza vaccination in children after haematopoietic stem cell transplantation. Br. J. Haematol. 127(3), 322-325 (2004). (Pubitemid 39468947)
95. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 86(2), 257-263 (2008).
96. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 54(RR-7), 1-21 (2005).
97. Parkkali T, Käyhty H, Lehtonen H et al. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients. Bone Marrow Transplant. 27(1), 79-84 (2001). (Pubitemid 32124410)
98. Mahler M, Kernan NA, Boulad F et al. Immunogenicity of the tetravalent protein-conjugated meningococcal vaccine in recipients of related and unrelated allogeneic hematopoietic cell transplants (HCT). Blood (2008) (Abstract 1163).
99. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Morb. Mortal. Wkly Rep. 58(14), 374-375 (2009).
100. Papadopoulos EB, Scurra Iovino C, Knowles MA et al. Pertussis response to TDaP (8 mcg pertussis toxoid/dose in recipients of allogeneic hematopoietic stem cell transplants (allo HSCT). Blood (2010) (Abstract 1282).
101. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: An update. Blood 115(10), 3861-3868 (2010). Excellent review of immune reconstitution post-HCT.
102. World Health Organization. Pneumococcal conjugate vaccines. Recommendation for the production and control of pneumococcal conjugate vaccines. WHO Tech. Rep. Ser. 927(annex 2), 64-98 (2005).
103. Vogel FR. Improving vaccine performance with adjuvants. Clin. Infect. Dis. 30(Suppl. 3), S266-S270 (2000). (Pubitemid 32250419)